mobihealthnews.com·May 13, 2026
Owkin has signed a three-year licensing agreement with AstraZeneca for its AI Scientist platform, K Pro, which is aimed at enhancing pharmaceutical research and decision-making.
Owkin's licensing agreement with AstraZeneca for their AI Scientist platform, K Pro, highlights a significant validation of AI's role in pharmaceutical research and decision support, underscoring a growing trend where major pharma companies are investing in AI tools to enhance drug discovery processes. This could signal potential investment opportunities or partnerships for those interested in the intersection of AI and pharmaceutical innovation.